KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Globus Medical (GMED) EBITDA (2016 - 2026)

Globus Medical filings provide 15 years of EBITDA readings, the most recent being $145.0 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 445.02% to $145.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $560.1 million, a 426.81% increase, with the full-year FY2025 number at $560.1 million, up 426.81% from a year prior.
  • EBITDA hit $145.0 million in Q4 2025 for Globus Medical, up from $119.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $215.3 million in Q2 2025 to a low of -$8.0 million in Q1 2024.
  • Median EBITDA over the past 5 years was $43.8 million (2021), compared with a mean of $55.7 million.
  • The widest YoY moves for EBITDA: up 4168.17% in 2024, down 114.67% in 2024.
  • Globus Medical's EBITDA stood at $11.4 million in 2021, then skyrocketed by 406.38% to $57.7 million in 2022, then plummeted by 59.11% to $23.6 million in 2023, then increased by 12.85% to $26.6 million in 2024, then skyrocketed by 445.02% to $145.0 million in 2025.
  • The last three reported values for EBITDA were $145.0 million (Q4 2025), $119.7 million (Q3 2025), and $215.3 million (Q2 2025) per Business Quant data.